NASDAQ:HALO Halozyme Therapeutics - HALO News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $33.68 +0.82 (+2.50%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$32.86▼$33.8550-Day Range$32.86▼$53.2852-Week Range$32.83▼$59.46Volume2.35 million shsAverage Volume1.56 million shsMarket Capitalization$4.56 billionP/E Ratio23.23Dividend YieldN/APrice Target$56.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.080.35▲Average Medical News Sentiment HALO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼173▲HALO Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFirst Hawaiian Bank Has $1.55 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)marketbeat.com - March 22 at 5:52 AMTitleist Asset Management LTD. Invests $273,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)marketbeat.com - March 21 at 7:49 AMHalozyme Therapeutics, Inc. Forecasted to Post Q3 2023 Earnings of $0.66 Per Share (NASDAQ:HALO)marketbeat.com - March 20 at 1:46 AMHalozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?finance.yahoo.com - March 23 at 5:54 PMHalozyme Therapeutics, Inc. to Post Q3 2023 Earnings of $0.66 Per Share, SVB Leerink Forecasts (NASDAQ:HALO)americanbankingnews.com - March 22 at 1:54 AMStrength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?finance.yahoo.com - March 21 at 7:53 AMHalozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year Low Following Analyst Downgradeamericanbankingnews.com - March 19 at 1:24 AMSVB Leerink Downgrades Halozyme Therapeutics to Market Perform, Announces $42 Price Targetbenzinga.com - March 18 at 8:51 PMHalozyme Therapeutics, Inc. Forecasted to Post Q4 2023 Earnings of $0.78 Per Share (NASDAQ:HALO)americanbankingnews.com - March 17 at 7:36 AMHalozyme Therapeutics' (HALO) Market Perform Rating Reaffirmed at SVB Leerinkamericanbankingnews.com - March 17 at 6:46 AMSVB Leerink Downgrades Halozyme Therapeutics (HALO)msn.com - March 16 at 7:31 PMThe Latest Analyst Ratings for Halozyme Therapeuticsmsn.com - March 16 at 2:31 PMDow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Planfinance.yahoo.com - March 16 at 2:31 PMGlobal Hyaluronidase Market Size by Application (Dermatology, Plastic Surgery) Forecast from 2023 to 2028marketwatch.com - March 15 at 1:54 PMHalozyme sees no impact on royalties after EU body revokes J&J's Darzalex patentmsn.com - March 15 at 1:54 PMHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPEfinance.yahoo.com - March 15 at 8:53 AMHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - March 15 at 3:48 AMHalozyme Therapeutics Stock (NASDAQ:HALO), Guidance and Forecastbenzinga.com - March 14 at 5:38 AMHalozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictionsbenzinga.com - March 13 at 7:37 PMImplied Volatility Surging for Halozyme Therapeutics (HALO) Stock Optionsfinance.yahoo.com - March 13 at 7:37 PMAntidiabetic Drug Market to 2023-2028marketwatch.com - March 10 at 3:44 AMHalozyme Therapeutics: A Trailblazer, But With Lukewarm Financialsseekingalpha.com - February 26 at 8:03 AMJP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $52benzinga.com - February 25 at 4:30 PMHalozyme Therapeutics Q4 EPS $0.42 Misses $0.47 Estimate, Sales $181.50M Miss $192.05M Estimatebenzinga.com - February 23 at 4:09 PMHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTSfinance.yahoo.com - February 21 at 9:29 PMBlackRock Increases Position in Halozyme Therapeutics247wallst.com - February 15 at 10:31 AMAre Options Traders Betting on a Big Move in Halozyme (HALO) Stock?finance.yahoo.com - February 10 at 1:52 PMHalozyme Appoints Barbara Duncan to its Board of Directorsfinance.yahoo.com - February 6 at 9:37 AMHyaluronidase Market Size in 2023 Industry Demand, Industry News, Business Growth, Top Key Players Update till 2028marketwatch.com - January 30 at 4:49 AMMultiple Reasons For the Outperformance of Halozyme Therapeutics (HALO)finance.yahoo.com - January 23 at 8:44 AMHalozyme (HALO) Down 9.2% on Weak 2023 Financial Guidancefinance.yahoo.com - January 12 at 2:59 PMHALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024finance.yahoo.com - January 11 at 1:21 PMAntidiabetic Drug Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028marketwatch.com - January 11 at 12:56 AMJMP Securities Keeps Their Buy Rating on Halozyme (HALO)markets.businessinsider.com - January 11 at 12:56 AMHalozyme Provides 2023 Financial Guidance and Outlookfinance.yahoo.com - January 10 at 7:55 PMHalo Therapeutics stock drops following weak 2023 outlookfinance.yahoo.com - January 10 at 7:55 PMHalozyme Therapeutics: Chugging Alongseekingalpha.com - January 9 at 10:46 PMWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Termfinance.yahoo.com - January 4 at 1:13 PMInvestors in Halozyme Therapeutics (NASDAQ:HALO) have made a solid return of 219% over the past three yearsfinance.yahoo.com - January 3 at 10:06 AMHalozyme to Present at the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 10:06 AMHalozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technologymsn.com - December 21 at 3:31 PMEpinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technaviofinance.yahoo.com - December 19 at 10:05 AMAntidiabetic Drug Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 Impactmarketwatch.com - December 12 at 10:46 AMWhere Halozyme Therapeutics Stands With Analystsmarkets.businessinsider.com - December 8 at 3:50 PMHalozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?finance.yahoo.com - December 8 at 3:50 PM5 Analysts Have This to Say About Halozyme Therapeuticsmarkets.businessinsider.com - December 8 at 9:18 AMEstimating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)finance.yahoo.com - December 7 at 7:23 AMLPCN: Focus on CNS Disordersfinance.yahoo.com - November 30 at 11:56 AM11 Best Diabetes Stocks To Buy Nowfinance.yahoo.com - November 27 at 5:48 PM4 Analysts Have This to Say About Halozyme Therapeuticsmarkets.businessinsider.com - November 22 at 6:14 PMHALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growthfinance.yahoo.com - November 15 at 3:03 PMShould You Hold Halozyme Therapeutics (HALO)?finance.yahoo.com - November 15 at 10:03 AMInterview With Quoc Tran of Tran Capitalfinance.yahoo.com - November 11 at 5:57 PM Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:HALO) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.